XML 46 R15.htm IDEA: XBRL DOCUMENT
v3.19.3

Segment Reporting | 9 Months Ended
--- | ---
Sep. 30, 2019
Segment Reporting [Abstract] |
SEGMENT REPORTING |
NOTE 9: | SEGMENT REPORTING
The Company has developed a genome editing platform and performed related research for human therapeutic and agricultural applications. The Company’s Chief Operating Decision Maker (“CODM”) evaluates the Company’s financial performance based on two reportable segments: Therapeutics and Food. The Therapeutics segment is focused on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment is focused on applying ARCUS to develop food and nutrition products through collaboration agreements with consumer-facing companies. The CODM reviews segment performance and allocates resources based upon segment revenue and segment operating loss of the Therapeutics and Food reportable segments. Segment operating loss is derived by deducting operational cash expenditures, net, from GAAP revenue. Operational cash expenditures are cash disbursements made that are directly attributable to the reportable segment (including directly attributable research and development and property, equipment, and software expenditures). For the nine months ended September 30, 2018, the Company allocated centralized research and development expenditures for early stage research, nuclease development and the purchase of general laboratory supplies to the Therapeutics and Food segments based on headcount. In January 2019, the Food segment moved into a new leased facility at Research Triangle Park, North Carolina. The Company has determined that the Food segment is no longer deriving benefit from the Company’s centralized research and development expenditures, thus all these expenditures are allocated to the Therapeutics segment for the nine months ended September 30, 2019. The reportable segment and centralized research and development operational cash expenditures include cash disbursements for compensation, laboratory supplies, purchases of property, equipment, and software and procuring services from CROs, CMOs, and research organizations. Certain cost items are not allocated to the Company’s reportable segments. These cost items primarily consist of compensation and general operational expenses associated with the Company’s executive, business development, finance, operations, human resources and legal functions. The Company does not allocate non-cash income statement amounts to its reportable segments, such as share based compensation, depreciation and amortization, intangible asset impairment charges, non-cash interest expense and losses on the disposal of assets. When reconciling segment operating loss to consolidated loss from operations, the Company makes an adjustment to convert the cash expenditures to the accrual basis to reflect GAAP. All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is the financial information with respect to the Company’s reportable segments:
|  | Three Months Ended September 30, |
(in thousands) |  | 2019 |  |  | 2018 |
Revenue: |  |  |  |  |  |  |  |
Therapeutics |  | $ | 4,719 |  |  | $ | 2,115 |
Food |  |  | 146 |  |  |  | 426 |
Total segment revenue |  |  | 4,865 |  |  |  | 2,541 |
Segment operational cash expenditures: |  |  |  |  |  |  |  |
Therapeutics |  | $ | 14,290 |  |  | $ | 11,727 |
Food |  |  | 1,942 |  |  |  | 857 |
Total segment operational cash expenditures |  |  | 16,232 |  |  |  | 12,584 |
Allocation of centralized research and development operational cash expenditures: |  |  |  |  |  |  |  |
Therapeutics |  | $ | 4,081 |  |  | $ | 2,387 |
Food |  |  | — |  |  |  | 597 |
Total allocation of centralized research and development operational cash expenditures |  |  | 4,081 |  |  |  | 2,984 |
Segment operating loss: |  |  |  |  |  |  |  |
Therapeutics |  | $ | (13,652 | ) |  | $ | (11,999 | )
Food |  |  | (1,796 | ) |  |  | (1,028 | )
Total segment operating loss |  |  | (15,448 | ) |  |  | (13,027 | )
Adjustments to reconcile segment operating loss to consolidated loss from operations: |  |  |  |  |  |  |  |
Corporate general and administrative cash expenditures |  | $ | (6,581 | ) |  | $ | (3,719 | )
Interest income received |  |  | (1,236 | ) |  |  | (691 | )
Depreciation and amortization |  |  | (1,401 | ) |  |  | (584 | )
Share-based compensation |  |  | (2,491 | ) |  |  | (292 | )
Changes in prepaid expenses, accounts payable and accrued expenses |  |  | 5,179 |  |  |  | 7,866 |
Total consolidated loss from operations |  | $ | (21,978 | ) |  | $ | (10,447 | )
|  | Nine Months Ended September 30, |
(in thousands) |  | 2019 |  |  | 2018 |
Revenue: |  |  |  |  |  |  |  |
Therapeutics |  | $ | 14,357 |  |  | $ | 5,009 |
Food |  |  | 1,359 |  |  |  | 934 |
Total segment revenue |  |  | 15,716 |  |  |  | 5,943 |
Segment operational cash expenditures: |  |  |  |  |  |  |  |
Therapeutics |  | $ | 42,072 |  |  | $ | 25,903 |
Food |  |  | 6,126 |  |  |  | 2,590 |
Total segment operational cash expenditures |  |  | 48,198 |  |  |  | 28,493 |
Allocation of centralized research and development operational cash expenditures: |  |  |  |  |  |  |  |
Therapeutics |  | $ | 10,952 |  |  | $ | 6,329 |
Food |  |  | — |  |  |  | 1,830 |
Total allocation of centralized research and development operational cash expenditures |  |  | 10,952 |  |  |  | 8,159 |
Segment operating loss: |  |  |  |  |  |  |  |
Therapeutics |  | $ | (38,667 | ) |  | $ | (27,223 | )
Food |  |  | (4,767 | ) |  |  | (3,486 | )
Total segment operating loss |  |  | (43,434 | ) |  |  | (30,709 | )
Adjustments to reconcile segment operating loss to consolidated loss from operations: |  |  |  |  |  |  |  |
Corporate general and administrative cash expenditures |  | $ | (24,726 | ) |  | $ | (8,397 | )
Interest income received |  |  | (3,322 | ) |  |  | (1,213 | )
Depreciation and amortization |  |  | (3,508 | ) |  |  | (1,555 | )
Share-based compensation |  |  | (6,319 | ) |  |  | (697 | )
Loss on disposal of assets |  |  | (22 | ) |  |  | (8 | )
Changes in prepaid expenses, accounts payable and accrued expenses |  |  | 15,988 |  |  |  | 10,772 |
Total consolidated loss from operations |  | $ | (65,343 | ) |  | $ | (31,807 | )

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration